333 related articles for article (PubMed ID: 16320850)
1. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
Khmara IM; Tolkachev IuV
Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
[TBL] [Abstract][Full Text] [Related]
2. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
4. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
5. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
6. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
7. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
[TBL] [Abstract][Full Text] [Related]
8. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
[TBL] [Abstract][Full Text] [Related]
9. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
10. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
11. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
La Vignera S; Vicari E; Tumino S; Ciotta L; Condorelli R; Vicari LO; Calogero AE
Minerva Ginecol; 2008 Dec; 60(6):475-84. PubMed ID: 18981975
[TBL] [Abstract][Full Text] [Related]
12. [Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
Eulry F; Bauduceau B; Lechevalier D; Magnin J; Crozes P; Flageat J; Gautier D
Rev Rhum Mal Osteoartic; 1992 Apr; 59(4):247-52. PubMed ID: 1496271
[TBL] [Abstract][Full Text] [Related]
13. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
14. Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal.
Lin SY; Huang SC; Sheu WH
Metabolism; 2010 Feb; 59(2):195-9. PubMed ID: 19765779
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
[TBL] [Abstract][Full Text] [Related]
16. Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism.
Laway BA; Goswami R; Singh N; Gupta N; Seith A
Clin Endocrinol (Oxf); 2006 Apr; 64(4):405-9. PubMed ID: 16584512
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
18. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment.
Eftekhari M; Asadollahi A; Beiki D; Izadyar S; Gholamrezanezhad A; Assadi M; Fard-Esfahani A; Fallahi B; Takavar A; Saghari M
Hell J Nucl Med; 2008; 11(3):160-3. PubMed ID: 19081859
[TBL] [Abstract][Full Text] [Related]
19. Influence of age and sex on bone mineral density in dialysis patients.
Grzegorzewska AE; Młot-Michalska M
Adv Perit Dial; 2007; 23():77-81. PubMed ID: 17886608
[TBL] [Abstract][Full Text] [Related]
20. Lumbar spine bone mineral density changes in patients with primary hyperparathyroidism according to age and gender.
Lumachi F; Camozzi V; Ermani M; Nardi A; Luisetto G
Ann N Y Acad Sci; 2007 Nov; 1117():362-6. PubMed ID: 17656570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
